Florida, US, Senate receives Rx Blueprint Plan for reducing spending and increase quality

31 March 2011

Public/Private Sector Strategies for America's Health Care Future (PS2) has delivered to the US state of Florida Senate President Mike Haridopolos (Republican, Melbourne) its report detailing how the state can reduce its spending on pharmaceuticals. The report makes recommendations in 21 areas that conservatively would save Florida taxpayers up to $170 million a year.

"Our charge was to identify steps the state could take that would result in maximum savings and at the same time mitigate the harm to those served by the various state programs," Jeffrey Lewis, president of PS2, said adding: "The PS2 blueprint provides the Legislature with a roadmap to achieve effective and important legislative changes to smart prescription drug purchasing and management. It demonstrates real solutions for real problems."

PS2's report, The Florida Rx Blueprint: Achieving Greater Savings for Florida's Taxpayers, is aimed at assisting public policymakers as they seek to reduce government spending. The report provides an explanation of the pharmaceutical problems the state faces and solutions to those problems. As the analysis notes, some of the issues involved are complicated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical